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to schizophrenia and does this variant have any effect on its function?
Computationalmethods can identify the potential targets for a partic-
ular miRNA based on the seed sequence it uses to bind to usually the 3′-
UTR of the target mRNA (Oulas et al., 2015). To determine which targets
are relevant to schizophrenia and worthy of further investigation, Wu et
al. (2016) searched their previous study of theHan Chinese (Zhang et al.,Schizophrenia is a complex disease believed to result from a combi-
nation of risk genes and environmental insults that change the trajecto-
ry of brain development. For decades researchers have strived to
unravel the genetic complexity of schizophrenia, using a variety of ap-
proaches. If one can understand the nature of the risk genes, then we
might better understand what causes schizophrenia, leading to better
diagnosis and treatment strategies.
One underlying theme has been to relate changes in genes to biolog-
ical dysfunction in the brain. Indeed, in the late 1990smany researchers
turned to microarray analyses of gene expression in attempts to under-
stand what genes have altered expression in the brain in schizophrenia
(Mirnics et al., 2000) and hence what biological pathways might be af-
fected. These studies showed that the expression of large numbers of
genes is altered in the brains of people with schizophrenia (Bowden et
al., 2008), but what caused this was unknown.
The central dogma of gene regulation that DNA codes for mRNA
which is translated into proteins, was challenged by the discovery of a
new mechanism for regulation of protein coding genes via non-coding
RNA species includingmicroRNAs (miRNA) (Lee et al., 1993). One single
miRNA could bind to and affect hundreds of mRNA transcripts and
might explain why so many genes are dysregulated in the brain in
schizophrenia. Subsequent studies in the post-mortembrains frompeo-
ple with schizophrenia identiﬁed signiﬁcant changes in miRNA expres-
sion (Beveridge et al., 2008). The potential importance of miRNA to
understanding the molecular basis of schizophrenia was further
highlighted when the Schizophrenia Working Group of the Psychiatric
Genetics Consortium conducted the largest ever genome wide associa-
tion study involving 36,989 cases and 113,075 controls (Ripke et al.,
2014). One of the strongest ﬁndings was a link between schizophrenia
and the genetic variant rs1625579 located in the intron that encodes a
miRNA calledmiR-137 (Ripke et al., 2014). SincemiRNA have hundredsm.2016.09.012.
. This is an open access article underof potential targets, the question is which miR-137 targets are relevant
2010) to identify genes linked to schizophrenia that contain the target se-
quence for miR-137. EFNB2 is such a gene that was linked to schizophre-
nia (Zhang et al., 2010), is functionally relevant to the disorder and is
predicted to be targeted by miR-137. Wu and colleagues used luciferase
reporter assays to show biologically that miR-137 targets the 3′ UTR of
EFNB2 and that the minor rs550067317 C allele variant at this site
disrupted this interaction (Wu et al., 2016). With the interaction
established, the task was then to determine whether miR-137 exerted
its effects directly on the post-transcriptional levels of EFNB2 mRNA or
protein. In a neuroblastoma cell line commonly used for neurobiological
studies, Wu and colleagues showed that miR-137 reduced the levels of
endogenous EFNB2 protein but not mRNA. This starts to tease out the
mechanism used by miR-137 to inﬂuence the functional roles of EFNB2.
There is also great interest to use information from schizophrenia-
associated genes as markers of schizophrenia phenotypes or as bio-
markers to assist in diagnosis. To do this, brain biopsies are not feasible
and ethical, so blood studies have been the main focus showing that
some gene expression changes in blood mimic what is seen in the
brain in schizophrenia (Sullivan et al., 2006). In 2013 a study showed
that a variant in theMIR137 gene when combined with severe negative
symptoms identiﬁed a subtype of schizophrenia sufferers with cogni-
tive deﬁcits (Green et al., 2013). To further this line of research, Wu
and colleagues showed that miR-137 but not EFNB2 expression was in-
creased in patients with schizophrenia compared to controls and that
this had some diagnostic value in distinguishing patients from controls
(Wu et al., 2016). Fig. 6B in the paper byWu and colleagues shows that
a subset of patients with schizophrenia have much higher miR-137 ex-
pression leaving you wondering what was their cognitive status?
Whilst the building evidence suggests miRNAs including miR-137
have a role in the development of schizophrenia andmay have some ca-
pacity as biomarkers, clearly further collaborative efforts will determine
how useful they are in understanding what causes schizophrenia,
whether they can assist with its diagnosis and importantly, whether
they provide insights on how to improve the current treatment options
for the disorder.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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